nodes	percent_of_prediction	percent_of_DWPC	metapath
Captopril—Enalapril—Lisinopril—systemic scleroderma	0.23	1	CrCrCtD
Captopril—MMP2—systemic scleroderma	0.182	0.475	CbGaD
Captopril—MMP9—systemic scleroderma	0.12	0.313	CbGaD
Captopril—ACE—Lisinopril—systemic scleroderma	0.111	0.52	CbGbCtD
Captopril—ACE—systemic scleroderma	0.0814	0.212	CbGaD
Captopril—SLC15A1—Lisinopril—systemic scleroderma	0.0446	0.209	CbGbCtD
Captopril—ALB—Mycophenolate mofetil—systemic scleroderma	0.0123	0.0577	CbGbCtD
Captopril—ABCB1—Lisinopril—systemic scleroderma	0.011	0.0512	CbGbCtD
Captopril—ALB—Prednisone—systemic scleroderma	0.00987	0.0461	CbGbCtD
Captopril—F2—cardial valve—systemic scleroderma	0.00648	0.111	CbGeAlD
Captopril—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00646	0.0302	CbGbCtD
Captopril—SLC22A6—Methotrexate—systemic scleroderma	0.00581	0.0272	CbGbCtD
Captopril—ABCB1—Prednisone—systemic scleroderma	0.00516	0.0241	CbGbCtD
Captopril—REN—forelimb zeugopod—systemic scleroderma	0.00503	0.0863	CbGeAlD
Captopril—ALB—Methotrexate—systemic scleroderma	0.00495	0.0231	CbGbCtD
Captopril—REN—pulmonary artery—systemic scleroderma	0.00376	0.0645	CbGeAlD
Captopril—MMP2—dermis—systemic scleroderma	0.00355	0.0609	CbGeAlD
Captopril—MMP2—FOXM1 transcription factor network—CENPB—systemic scleroderma	0.00336	0.0745	CbGpPWpGaD
Captopril—MMP9—dermis—systemic scleroderma	0.00309	0.0529	CbGeAlD
Captopril—MMP2—skeletal joint—systemic scleroderma	0.00306	0.0525	CbGeAlD
Captopril—MMP9—skeletal joint—systemic scleroderma	0.00266	0.0457	CbGeAlD
Captopril—ABCB1—Methotrexate—systemic scleroderma	0.00259	0.0121	CbGbCtD
Captopril—REN—Metabolism of Angiotensinogen to Angiotensins—ACE—systemic scleroderma	0.00229	0.0507	CbGpPWpGaD
Captopril—REN—ACE Inhibitor Pathway—ACE—systemic scleroderma	0.00218	0.0483	CbGpPWpGaD
Captopril—ACE—forelimb zeugopod—systemic scleroderma	0.00214	0.0368	CbGeAlD
Captopril—ACE—pulmonary artery—systemic scleroderma	0.0016	0.0275	CbGeAlD
Captopril—ACE—skeletal joint—systemic scleroderma	0.00142	0.0244	CbGeAlD
Captopril—REN—artery—systemic scleroderma	0.00139	0.0239	CbGeAlD
Captopril—MMP2—artery—systemic scleroderma	0.00128	0.022	CbGeAlD
Captopril—MMP9—artery—systemic scleroderma	0.00112	0.0191	CbGeAlD
Captopril—REN—blood vessel—systemic scleroderma	0.00109	0.0186	CbGeAlD
Captopril—MMP2—endothelium—systemic scleroderma	0.00108	0.0186	CbGeAlD
Captopril—ACE—umbilical vein—systemic scleroderma	0.00106	0.0182	CbGeAlD
Captopril—MMP2—amb2 Integrin signaling—SELP—systemic scleroderma	0.00104	0.0232	CbGpPWpGaD
Captopril—REN—ACE Inhibitor Pathway—NOS3—systemic scleroderma	0.00101	0.0225	CbGpPWpGaD
Captopril—MMP2—blood vessel—systemic scleroderma	0.000999	0.0171	CbGeAlD
Captopril—F2—artery—systemic scleroderma	0.000973	0.0167	CbGeAlD
Captopril—Enalapril—ACE—systemic scleroderma	0.000954	1	CrCbGaD
Captopril—MMP9—endothelium—systemic scleroderma	0.000942	0.0162	CbGeAlD
Captopril—MMP2—FOXM1 transcription factor network—CENPA—systemic scleroderma	0.000887	0.0197	CbGpPWpGaD
Captopril—MMP9—blood vessel—systemic scleroderma	0.000869	0.0149	CbGeAlD
Captopril—MMP2—amb2 Integrin signaling—ITGAM—systemic scleroderma	0.000835	0.0185	CbGpPWpGaD
Captopril—F2—endothelium—systemic scleroderma	0.000822	0.0141	CbGeAlD
Captopril—MMP2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—COL1A2—systemic scleroderma	0.000819	0.0182	CbGpPWpGaD
Captopril—MMP2—Enalapril—Lisinopril—systemic scleroderma	0.000817	0.569	CbGdCrCtD
Captopril—F2—blood vessel—systemic scleroderma	0.000758	0.013	CbGeAlD
Captopril—LTA4H—connective tissue—systemic scleroderma	0.000722	0.0124	CbGeAlD
Captopril—MMP2—amb2 Integrin signaling—CTGF—systemic scleroderma	0.000697	0.0155	CbGpPWpGaD
Captopril—MMP9—amb2 Integrin signaling—SELP—systemic scleroderma	0.000685	0.0152	CbGpPWpGaD
Captopril—REN—ACE Inhibitor Pathway—TGFB1—systemic scleroderma	0.00067	0.0148	CbGpPWpGaD
Captopril—LTA4H—smooth muscle tissue—systemic scleroderma	0.00066	0.0113	CbGeAlD
Captopril—REN—Peptide hormone metabolism—ACE—systemic scleroderma	0.000601	0.0133	CbGpPWpGaD
Captopril—ACE—artery—systemic scleroderma	0.000594	0.0102	CbGeAlD
Captopril—MMP2—Regulation of IGF Activity by IGFBP—MMP1—systemic scleroderma	0.000586	0.013	CbGpPWpGaD
Captopril—REN—connective tissue—systemic scleroderma	0.000557	0.00956	CbGeAlD
Captopril—MMP9—Spinal Cord Injury—AIF1—systemic scleroderma	0.000554	0.0123	CbGpPWpGaD
Captopril—MMP9—amb2 Integrin signaling—ITGAM—systemic scleroderma	0.000548	0.0121	CbGpPWpGaD
Captopril—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—COL1A2—systemic scleroderma	0.000537	0.0119	CbGpPWpGaD
Captopril—MMP9—Syndecan-1-mediated signaling events—COL1A2—systemic scleroderma	0.000526	0.0117	CbGpPWpGaD
Captopril—LTA4H—digestive system—systemic scleroderma	0.000521	0.00894	CbGeAlD
Captopril—MMP2—connective tissue—systemic scleroderma	0.000512	0.00878	CbGeAlD
Captopril—REN—smooth muscle tissue—systemic scleroderma	0.00051	0.00874	CbGeAlD
Captopril—ACE—endothelium—systemic scleroderma	0.000502	0.00861	CbGeAlD
Captopril—LTA4H—tendon—systemic scleroderma	0.000496	0.00851	CbGeAlD
Captopril—MMP2—smooth muscle tissue—systemic scleroderma	0.000468	0.00804	CbGeAlD
Captopril—ACE—blood vessel—systemic scleroderma	0.000463	0.00794	CbGeAlD
Captopril—MMP2—skin of body—systemic scleroderma	0.000462	0.00793	CbGeAlD
Captopril—MMP9—amb2 Integrin signaling—CTGF—systemic scleroderma	0.000457	0.0101	CbGpPWpGaD
Captopril—ACE—ACE Inhibitor Pathway—NOS3—systemic scleroderma	0.000453	0.01	CbGpPWpGaD
Captopril—MMP9—connective tissue—systemic scleroderma	0.000445	0.00764	CbGeAlD
Captopril—MMP9—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—ITGAM—systemic scleroderma	0.000441	0.00977	CbGpPWpGaD
Captopril—MMP2—Matrix Metalloproteinases—MMP1—systemic scleroderma	0.000441	0.00977	CbGpPWpGaD
Captopril—LTA4H—lung—systemic scleroderma	0.000435	0.00747	CbGeAlD
Captopril—MMP2—Direct p53 effectors—GDF15—systemic scleroderma	0.000434	0.00963	CbGpPWpGaD
Captopril—MMP2—Activation of Matrix Metalloproteinases—MMP1—systemic scleroderma	0.000419	0.00928	CbGpPWpGaD
Captopril—MMP9—Assembly of collagen fibrils and other multimeric structures—COL1A2—systemic scleroderma	0.000409	0.00907	CbGpPWpGaD
Captopril—MMP9—smooth muscle tissue—systemic scleroderma	0.000407	0.00699	CbGeAlD
Captopril—MMP2—Degradation of the extracellular matrix—HSPG2—systemic scleroderma	0.000406	0.00899	CbGpPWpGaD
Captopril—REN—digestive system—systemic scleroderma	0.000402	0.0069	CbGeAlD
Captopril—MMP9—skin of body—systemic scleroderma	0.000402	0.0069	CbGeAlD
Captopril—F2—Platelet Aggregation (Plug Formation)—CSK—systemic scleroderma	0.000401	0.00888	CbGpPWpGaD
Captopril—F2—connective tissue—systemic scleroderma	0.000389	0.00667	CbGeAlD
Captopril—MMP2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP1—systemic scleroderma	0.000373	0.00826	CbGpPWpGaD
Captopril—MMP2—digestive system—systemic scleroderma	0.00037	0.00634	CbGeAlD
Captopril—MMP2—Collagen degradation—MMP1—systemic scleroderma	0.000365	0.00809	CbGpPWpGaD
Captopril—MMP2—tendon—systemic scleroderma	0.000352	0.00604	CbGeAlD
Captopril—REN—lung—systemic scleroderma	0.000336	0.00576	CbGeAlD
Captopril—MMP9—AP-1 transcription factor network—COL1A2—systemic scleroderma	0.000323	0.00715	CbGpPWpGaD
Captopril—MMP9—digestive system—systemic scleroderma	0.000322	0.00552	CbGeAlD
Captopril—MMP2—lung—systemic scleroderma	0.000309	0.0053	CbGeAlD
Captopril—MMP9—tendon—systemic scleroderma	0.000306	0.00525	CbGeAlD
Captopril—MMP2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCL2—systemic scleroderma	0.000303	0.00672	CbGpPWpGaD
Captopril—ACE—ACE Inhibitor Pathway—TGFB1—systemic scleroderma	0.000299	0.00663	CbGpPWpGaD
Captopril—F2—Regulation of IGF Activity by IGFBP—MMP1—systemic scleroderma	0.000297	0.00658	CbGpPWpGaD
Captopril—MMP9—CXCR4-mediated signaling events—RHOB—systemic scleroderma	0.000296	0.00655	CbGpPWpGaD
Captopril—MMP9—Matrix Metalloproteinases—MMP1—systemic scleroderma	0.000289	0.00641	CbGpPWpGaD
Captopril—F2—Folate Metabolism—CSF1—systemic scleroderma	0.000286	0.00634	CbGpPWpGaD
Captopril—MMP9—IL1 and megakaryotyces in obesity—CCL2—systemic scleroderma	0.000281	0.00623	CbGpPWpGaD
Captopril—F2—digestive system—systemic scleroderma	0.000281	0.00481	CbGeAlD
Captopril—MMP9—Collagen formation—COL1A2—systemic scleroderma	0.000279	0.00618	CbGpPWpGaD
Captopril—MMP9—Activation of Matrix Metalloproteinases—MMP1—systemic scleroderma	0.000275	0.00609	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.000271	0.006	CbGpPWpGaD
Captopril—MMP2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—NOS3—systemic scleroderma	0.00027	0.00599	CbGpPWpGaD
Captopril—MMP9—CXCR4-mediated signaling events—CSK—systemic scleroderma	0.000269	0.00597	CbGpPWpGaD
Captopril—MMP9—lung—systemic scleroderma	0.000269	0.00461	CbGeAlD
Captopril—MMP2—Direct p53 effectors—IRF5—systemic scleroderma	0.000268	0.00595	CbGpPWpGaD
Captopril—MMP9—Degradation of the extracellular matrix—HSPG2—systemic scleroderma	0.000266	0.0059	CbGpPWpGaD
Captopril—MMP2—Matrix Metalloproteinases—MMP9—systemic scleroderma	0.000256	0.00568	CbGpPWpGaD
Captopril—MMP9—CXCR4-mediated signaling events—CD247—systemic scleroderma	0.000253	0.00561	CbGpPWpGaD
Captopril—MMP9—Angiogenesis—NOS3—systemic scleroderma	0.000251	0.00555	CbGpPWpGaD
Captopril—MMP2—Osteopontin-mediated events—MMP9—systemic scleroderma	0.00025	0.00553	CbGpPWpGaD
Captopril—MMP2—Plasma membrane estrogen receptor signaling—NOS3—systemic scleroderma	0.000249	0.00552	CbGpPWpGaD
Captopril—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP1—systemic scleroderma	0.000244	0.00542	CbGpPWpGaD
Captopril—MMP2—amb2 Integrin signaling—MMP9—systemic scleroderma	0.000243	0.0054	CbGpPWpGaD
Captopril—MMP2—Activation of Matrix Metalloproteinases—MMP9—systemic scleroderma	0.000243	0.0054	CbGpPWpGaD
Captopril—MMP2—Extracellular matrix organization—FBN1—systemic scleroderma	0.000243	0.00539	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—SELP—systemic scleroderma	0.000241	0.00535	CbGpPWpGaD
Captopril—MMP9—Syndecan-1-mediated signaling events—MMP1—systemic scleroderma	0.000239	0.0053	CbGpPWpGaD
Captopril—MMP9—Collagen degradation—MMP1—systemic scleroderma	0.000239	0.0053	CbGpPWpGaD
Captopril—SLC15A1—digestive system—systemic scleroderma	0.000239	0.0041	CbGeAlD
Captopril—ACE—connective tissue—systemic scleroderma	0.000237	0.00407	CbGeAlD
Captopril—F2—lung—systemic scleroderma	0.000234	0.00402	CbGeAlD
Captopril—MMP9—CXCR4-mediated signaling events—BLK—systemic scleroderma	0.000234	0.00519	CbGpPWpGaD
Captopril—F2—Regulation of IGF Activity by IGFBP—MMP2—systemic scleroderma	0.00023	0.00509	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—RHOB—systemic scleroderma	0.000225	0.00499	CbGpPWpGaD
Captopril—MMP9—Matrix Metalloproteinases—MMP2—systemic scleroderma	0.000224	0.00496	CbGpPWpGaD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000223	0.00495	CbGpPWpGaD
Captopril—MMP9—Osteopontin-mediated events—MMP2—systemic scleroderma	0.000218	0.00483	CbGpPWpGaD
Captopril—ACE—smooth muscle tissue—systemic scleroderma	0.000217	0.00373	CbGeAlD
Captopril—F2—IL1 and megakaryotyces in obesity—CCL2—systemic scleroderma	0.000217	0.00481	CbGpPWpGaD
Captopril—MMP2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP9—systemic scleroderma	0.000217	0.0048	CbGpPWpGaD
Captopril—F2—Cell surface interactions at the vascular wall—SELP—systemic scleroderma	0.000214	0.00475	CbGpPWpGaD
Captopril—MMP9—IL1 and megakaryotyces in obesity—IL1B—systemic scleroderma	0.000213	0.00473	CbGpPWpGaD
Captopril—MMP9—Activation of Matrix Metalloproteinases—MMP2—systemic scleroderma	0.000212	0.00471	CbGpPWpGaD
Captopril—MMP9—amb2 Integrin signaling—MMP2—systemic scleroderma	0.000212	0.00471	CbGpPWpGaD
Captopril—MMP2—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic scleroderma	0.000212	0.00471	CbGpPWpGaD
Captopril—MMP2—Collagen degradation—MMP9—systemic scleroderma	0.000212	0.0047	CbGpPWpGaD
Captopril—MMP2—Betamethasone—Mometasone—systemic scleroderma	0.000201	0.14	CbGdCrCtD
Captopril—MMP2—Dexamethasone—Mometasone—systemic scleroderma	0.000201	0.14	CbGdCrCtD
Captopril—MMP2—Plasma membrane estrogen receptor signaling—MMP9—systemic scleroderma	0.0002	0.00443	CbGpPWpGaD
Captopril—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCL2—systemic scleroderma	0.000199	0.00441	CbGpPWpGaD
Captopril—ALB—Lipoprotein metabolism—HSPG2—systemic scleroderma	0.000195	0.00431	CbGpPWpGaD
Captopril—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—systemic scleroderma	0.000189	0.00419	CbGpPWpGaD
Captopril—MMP9—Collagen degradation—MMP2—systemic scleroderma	0.000185	0.0041	CbGpPWpGaD
Captopril—MMP2—Degradation of the extracellular matrix—MMP1—systemic scleroderma	0.000185	0.00409	CbGpPWpGaD
Captopril—MMP2—Syndecan-2-mediated signaling events—TGFB1—systemic scleroderma	0.000183	0.00405	CbGpPWpGaD
Captopril—MMP9—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.00018	0.00398	CbGpPWpGaD
Captopril—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—NOS3—systemic scleroderma	0.000177	0.00393	CbGpPWpGaD
Captopril—MMP2—EPH-ephrin mediated repulsion of cells—MMP9—systemic scleroderma	0.000176	0.0039	CbGpPWpGaD
Captopril—MMP9—AP-1 transcription factor network—EDN1—systemic scleroderma	0.000175	0.00387	CbGpPWpGaD
Captopril—MMP9—Plasma membrane estrogen receptor signaling—MMP2—systemic scleroderma	0.000174	0.00386	CbGpPWpGaD
Captopril—ACE—digestive system—systemic scleroderma	0.000171	0.00294	CbGeAlD
Captopril—F2—Cell surface interactions at the vascular wall—ITGAM—systemic scleroderma	0.000171	0.0038	CbGpPWpGaD
Captopril—MMP2—Extracellular matrix organization—COL1A2—systemic scleroderma	0.00017	0.00377	CbGpPWpGaD
Captopril—MMP2—Extracellular matrix organization—HSPG2—systemic scleroderma	0.00017	0.00377	CbGpPWpGaD
Captopril—MMP2—AGE/RAGE pathway—NOS3—systemic scleroderma	0.00017	0.00377	CbGpPWpGaD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000169	0.00375	CbGpPWpGaD
Captopril—F2—IL1 and megakaryotyces in obesity—IL1B—systemic scleroderma	0.000165	0.00365	CbGpPWpGaD
Captopril—MMP9—Plasma membrane estrogen receptor signaling—NOS3—systemic scleroderma	0.000163	0.00362	CbGpPWpGaD
Captopril—ABCB1—blood vessel—systemic scleroderma	0.000163	0.0028	CbGeAlD
Captopril—MMP9—Extracellular matrix organization—FBN1—systemic scleroderma	0.000159	0.00353	CbGpPWpGaD
Captopril—F2—IL1 and megakaryotyces in obesity—MMP9—systemic scleroderma	0.000155	0.00344	CbGpPWpGaD
Captopril—MMP2—Extracellular matrix organization—ITGAM—systemic scleroderma	0.000154	0.00342	CbGpPWpGaD
Captopril—MMP9—EPH-ephrin mediated repulsion of cells—MMP2—systemic scleroderma	0.000154	0.0034	CbGpPWpGaD
Captopril—MMP2—Axon guidance—RHOB—systemic scleroderma	0.000153	0.00339	CbGpPWpGaD
Captopril—ALB—Binding and Uptake of Ligands by Scavenger Receptors—COL1A2—systemic scleroderma	0.000152	0.00336	CbGpPWpGaD
Captopril—MMP9—AP-1 transcription factor network—MMP1—systemic scleroderma	0.000147	0.00325	CbGpPWpGaD
Captopril—ACE—lung—systemic scleroderma	0.000143	0.00246	CbGeAlD
Captopril—MMP2—LPA receptor mediated events—MMP9—systemic scleroderma	0.00014	0.0031	CbGpPWpGaD
Captopril—MMP2—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000136	0.00302	CbGpPWpGaD
Captopril—F2—Regulation of Actin Cytoskeleton—CSK—systemic scleroderma	0.000131	0.00291	CbGpPWpGaD
Captopril—ALB—Lipid and lipoprotein metabolism—HSPG2—systemic scleroderma	0.000129	0.00287	CbGpPWpGaD
Captopril—F2—Syndecan-4-mediated signaling events—MMP9—systemic scleroderma	0.000123	0.00273	CbGpPWpGaD
Captopril—MMP9—LPA receptor mediated events—MMP2—systemic scleroderma	0.000122	0.0027	CbGpPWpGaD
Captopril—F2—PAR1-mediated thrombin signaling events—NOS3—systemic scleroderma	0.000121	0.00269	CbGpPWpGaD
Captopril—MMP9—Degradation of the extracellular matrix—MMP1—systemic scleroderma	0.000121	0.00268	CbGpPWpGaD
Captopril—MMP9—AP-1 transcription factor network—CCL2—systemic scleroderma	0.000119	0.00265	CbGpPWpGaD
Captopril—MMP9—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000119	0.00264	CbGpPWpGaD
Captopril—F2—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.000119	0.00263	CbGpPWpGaD
Captopril—MMP2—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—systemic scleroderma	0.000117	0.00259	CbGpPWpGaD
Captopril—F2—Angiopoietin receptor Tie2-mediated signaling—MMP2—systemic scleroderma	0.000115	0.00254	CbGpPWpGaD
Captopril—MMP9—Syndecan-1-mediated signaling events—TGFB1—systemic scleroderma	0.000115	0.00254	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—IL1A—systemic scleroderma	0.000114	0.00253	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—CSF1—systemic scleroderma	0.000114	0.00252	CbGpPWpGaD
Captopril—REN—Metabolism of proteins—ACE—systemic scleroderma	0.000113	0.00251	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000113	0.0025	CbGpPWpGaD
Captopril—MMP9—Extracellular matrix organization—HSPG2—systemic scleroderma	0.000112	0.00247	CbGpPWpGaD
Captopril—MMP9—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000112	0.00247	CbGpPWpGaD
Captopril—MMP9—Extracellular matrix organization—COL1A2—systemic scleroderma	0.000112	0.00247	CbGpPWpGaD
Captopril—MMP2—Dexamethasone—Prednisone—systemic scleroderma	0.000109	0.0761	CbGdCrCtD
Captopril—MMP2—Betamethasone—Prednisone—systemic scleroderma	0.000109	0.0761	CbGdCrCtD
Captopril—MMP2—Developmental Biology—RHOB—systemic scleroderma	0.000109	0.00242	CbGpPWpGaD
Captopril—F2—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic scleroderma	0.000108	0.00238	CbGpPWpGaD
Captopril—MMP2—Degradation of the extracellular matrix—MMP9—systemic scleroderma	0.000107	0.00238	CbGpPWpGaD
Captopril—MMP9—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—TGFB1—systemic scleroderma	0.000106	0.00235	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000105	0.00233	CbGpPWpGaD
Captopril—MMP2—EPH-Ephrin signaling—MMP9—systemic scleroderma	0.000103	0.00228	CbGpPWpGaD
Captopril—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—systemic scleroderma	0.000102	0.00226	CbGpPWpGaD
Captopril—MMP9—Extracellular matrix organization—ITGAM—systemic scleroderma	0.000101	0.00224	CbGpPWpGaD
Captopril—ALB—Platelet degranulation—SELP—systemic scleroderma	0.000101	0.00224	CbGpPWpGaD
Captopril—MMP9—Axon guidance—RHOB—systemic scleroderma	0.0001	0.00223	CbGpPWpGaD
Captopril—LTA4H—Metabolism—HSPG2—systemic scleroderma	9.95e-05	0.00221	CbGpPWpGaD
Captopril—F2—Folate Metabolism—CCL2—systemic scleroderma	9.66e-05	0.00214	CbGpPWpGaD
Captopril—ALB—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	9.61e-05	0.00213	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	9.59e-05	0.00213	CbGpPWpGaD
Captopril—MMP9—Degradation of the extracellular matrix—MMP2—systemic scleroderma	9.37e-05	0.00208	CbGpPWpGaD
Captopril—F2—Vitamin B12 Metabolism—IL1B—systemic scleroderma	9.01e-05	0.002	CbGpPWpGaD
Captopril—MMP9—EPH-Ephrin signaling—MMP2—systemic scleroderma	8.97e-05	0.00199	CbGpPWpGaD
Captopril—CYP2D6—Melatonin metabolism and effects—EDN1—systemic scleroderma	8.94e-05	0.00198	CbGpPWpGaD
Captopril—F2—Cell surface interactions at the vascular wall—MMP1—systemic scleroderma	8.59e-05	0.0019	CbGpPWpGaD
Captopril—CYP2D6—digestive system—systemic scleroderma	8.39e-05	0.00144	CbGeAlD
Captopril—MMP9—Spinal Cord Injury—CCL2—systemic scleroderma	7.86e-05	0.00174	CbGpPWpGaD
Captopril—Confusional state—Mycophenolic acid—systemic scleroderma	7.84e-05	0.00118	CcSEcCtD
Captopril—Anorexia—Leflunomide—systemic scleroderma	7.77e-05	0.00117	CcSEcCtD
Captopril—Nausea—Pentoxifylline—systemic scleroderma	7.75e-05	0.00117	CcSEcCtD
Captopril—Malaise—Lisinopril—systemic scleroderma	7.74e-05	0.00116	CcSEcCtD
Captopril—MMP2—Extracellular matrix organization—MMP1—systemic scleroderma	7.74e-05	0.00171	CbGpPWpGaD
Captopril—Diarrhoea—Mometasone—systemic scleroderma	7.71e-05	0.00116	CcSEcCtD
Captopril—Syncope—Lisinopril—systemic scleroderma	7.7e-05	0.00116	CcSEcCtD
Captopril—F2—Selenium Micronutrient Network—CCL2—systemic scleroderma	7.68e-05	0.0017	CbGpPWpGaD
Captopril—Renal failure acute—Methotrexate—systemic scleroderma	7.66e-05	0.00115	CcSEcCtD
Captopril—Shock—Mycophenolic acid—systemic scleroderma	7.65e-05	0.00115	CcSEcCtD
Captopril—Alopecia—Mycophenolate mofetil—systemic scleroderma	7.64e-05	0.00115	CcSEcCtD
Captopril—Hypotension—Leflunomide—systemic scleroderma	7.62e-05	0.00115	CcSEcCtD
Captopril—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	7.62e-05	0.00115	CcSEcCtD
Captopril—Tachycardia—Mycophenolic acid—systemic scleroderma	7.59e-05	0.00114	CcSEcCtD
Captopril—Palpitations—Lisinopril—systemic scleroderma	7.59e-05	0.00114	CcSEcCtD
Captopril—MMP9—Endochondral Ossification—TGFB1—systemic scleroderma	7.56e-05	0.00168	CbGpPWpGaD
Captopril—Loss of consciousness—Lisinopril—systemic scleroderma	7.55e-05	0.00113	CcSEcCtD
Captopril—LTA4H—Metabolism—CTGF—systemic scleroderma	7.54e-05	0.00167	CbGpPWpGaD
Captopril—Dermatitis exfoliative—Methotrexate—systemic scleroderma	7.5e-05	0.00113	CcSEcCtD
Captopril—Cough—Lisinopril—systemic scleroderma	7.49e-05	0.00113	CcSEcCtD
Captopril—Muscular weakness—Prednisone—systemic scleroderma	7.47e-05	0.00112	CcSEcCtD
Captopril—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	7.43e-05	0.00112	CcSEcCtD
Captopril—Anorexia—Mycophenolic acid—systemic scleroderma	7.42e-05	0.00112	CcSEcCtD
Captopril—Tension—Mycophenolate mofetil—systemic scleroderma	7.38e-05	0.00111	CcSEcCtD
Captopril—Insomnia—Leflunomide—systemic scleroderma	7.38e-05	0.00111	CcSEcCtD
Captopril—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	7.37e-05	0.00111	CcSEcCtD
Captopril—F2—Folate Metabolism—IL1B—systemic scleroderma	7.33e-05	0.00162	CbGpPWpGaD
Captopril—Paraesthesia—Leflunomide—systemic scleroderma	7.32e-05	0.0011	CcSEcCtD
Captopril—Anaphylactoid reaction—Methotrexate—systemic scleroderma	7.31e-05	0.0011	CcSEcCtD
Captopril—Arthralgia—Lisinopril—systemic scleroderma	7.31e-05	0.0011	CcSEcCtD
Captopril—Myalgia—Lisinopril—systemic scleroderma	7.31e-05	0.0011	CcSEcCtD
Captopril—Chest pain—Lisinopril—systemic scleroderma	7.31e-05	0.0011	CcSEcCtD
Captopril—Nervousness—Mycophenolate mofetil—systemic scleroderma	7.31e-05	0.0011	CcSEcCtD
Captopril—REN—Metabolism of proteins—MMP1—systemic scleroderma	7.28e-05	0.00161	CbGpPWpGaD
Captopril—Dyspnoea—Leflunomide—systemic scleroderma	7.27e-05	0.00109	CcSEcCtD
Captopril—Hypotension—Mycophenolic acid—systemic scleroderma	7.27e-05	0.00109	CcSEcCtD
Captopril—Discomfort—Lisinopril—systemic scleroderma	7.22e-05	0.00109	CcSEcCtD
Captopril—Cerebrovascular accident—Methotrexate—systemic scleroderma	7.22e-05	0.00109	CcSEcCtD
Captopril—Dyspepsia—Leflunomide—systemic scleroderma	7.18e-05	0.00108	CcSEcCtD
Captopril—Pancreatitis—Prednisone—systemic scleroderma	7.17e-05	0.00108	CcSEcCtD
Captopril—MMP9—Developmental Biology—RHOB—systemic scleroderma	7.16e-05	0.00159	CbGpPWpGaD
Captopril—Vomiting—Mometasone—systemic scleroderma	7.16e-05	0.00108	CcSEcCtD
Captopril—Dry mouth—Lisinopril—systemic scleroderma	7.15e-05	0.00108	CcSEcCtD
Captopril—Feeling abnormal—Azathioprine—systemic scleroderma	7.12e-05	0.00107	CcSEcCtD
Captopril—Rash—Mometasone—systemic scleroderma	7.1e-05	0.00107	CcSEcCtD
Captopril—Dermatitis—Mometasone—systemic scleroderma	7.1e-05	0.00107	CcSEcCtD
Captopril—Decreased appetite—Leflunomide—systemic scleroderma	7.09e-05	0.00107	CcSEcCtD
Captopril—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	7.09e-05	0.00107	CcSEcCtD
Captopril—Confusional state—Lisinopril—systemic scleroderma	7.06e-05	0.00106	CcSEcCtD
Captopril—Gastrointestinal pain—Azathioprine—systemic scleroderma	7.06e-05	0.00106	CcSEcCtD
Captopril—Headache—Mometasone—systemic scleroderma	7.06e-05	0.00106	CcSEcCtD
Captopril—MMP9—AP-1 transcription factor network—TGFB1—systemic scleroderma	7.04e-05	0.00156	CbGpPWpGaD
Captopril—Insomnia—Mycophenolic acid—systemic scleroderma	7.04e-05	0.00106	CcSEcCtD
Captopril—Fatigue—Leflunomide—systemic scleroderma	7.03e-05	0.00106	CcSEcCtD
Captopril—Anaphylactic shock—Lisinopril—systemic scleroderma	7.01e-05	0.00105	CcSEcCtD
Captopril—Paraesthesia—Mycophenolic acid—systemic scleroderma	6.99e-05	0.00105	CcSEcCtD
Captopril—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	6.98e-05	0.00105	CcSEcCtD
Captopril—Constipation—Leflunomide—systemic scleroderma	6.97e-05	0.00105	CcSEcCtD
Captopril—Anaemia—Mycophenolate mofetil—systemic scleroderma	6.95e-05	0.00105	CcSEcCtD
Captopril—Dyspnoea—Mycophenolic acid—systemic scleroderma	6.94e-05	0.00104	CcSEcCtD
Captopril—Somnolence—Mycophenolic acid—systemic scleroderma	6.92e-05	0.00104	CcSEcCtD
Captopril—Shock—Lisinopril—systemic scleroderma	6.89e-05	0.00104	CcSEcCtD
Captopril—Angioedema—Mycophenolate mofetil—systemic scleroderma	6.87e-05	0.00103	CcSEcCtD
Captopril—Thrombocytopenia—Lisinopril—systemic scleroderma	6.86e-05	0.00103	CcSEcCtD
Captopril—Dyspepsia—Mycophenolic acid—systemic scleroderma	6.85e-05	0.00103	CcSEcCtD
Captopril—Neutropenia—Prednisone—systemic scleroderma	6.84e-05	0.00103	CcSEcCtD
Captopril—Tachycardia—Lisinopril—systemic scleroderma	6.84e-05	0.00103	CcSEcCtD
Captopril—Body temperature increased—Azathioprine—systemic scleroderma	6.83e-05	0.00103	CcSEcCtD
Captopril—Abdominal pain—Azathioprine—systemic scleroderma	6.83e-05	0.00103	CcSEcCtD
Captopril—Malaise—Mycophenolate mofetil—systemic scleroderma	6.78e-05	0.00102	CcSEcCtD
Captopril—Decreased appetite—Mycophenolic acid—systemic scleroderma	6.76e-05	0.00102	CcSEcCtD
Captopril—Syncope—Mycophenolate mofetil—systemic scleroderma	6.75e-05	0.00101	CcSEcCtD
Captopril—Erectile dysfunction—Prednisone—systemic scleroderma	6.74e-05	0.00101	CcSEcCtD
Captopril—ABCB1—Allograft Rejection—IL13—systemic scleroderma	6.72e-05	0.00149	CbGpPWpGaD
Captopril—Feeling abnormal—Leflunomide—systemic scleroderma	6.72e-05	0.00101	CcSEcCtD
Captopril—Fatigue—Mycophenolic acid—systemic scleroderma	6.71e-05	0.00101	CcSEcCtD
Captopril—Nausea—Mometasone—systemic scleroderma	6.69e-05	0.00101	CcSEcCtD
Captopril—Anorexia—Lisinopril—systemic scleroderma	6.68e-05	0.001	CcSEcCtD
Captopril—Gastrointestinal pain—Leflunomide—systemic scleroderma	6.67e-05	0.001	CcSEcCtD
Captopril—Ataxia—Methotrexate—systemic scleroderma	6.65e-05	0.001	CcSEcCtD
Captopril—Constipation—Mycophenolic acid—systemic scleroderma	6.65e-05	0.001	CcSEcCtD
Captopril—Palpitations—Mycophenolate mofetil—systemic scleroderma	6.65e-05	0.001	CcSEcCtD
Captopril—Weight decreased—Prednisone—systemic scleroderma	6.62e-05	0.000996	CcSEcCtD
Captopril—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	6.61e-05	0.000994	CcSEcCtD
Captopril—Cough—Mycophenolate mofetil—systemic scleroderma	6.56e-05	0.000987	CcSEcCtD
Captopril—Hypotension—Lisinopril—systemic scleroderma	6.55e-05	0.000985	CcSEcCtD
Captopril—Body temperature increased—Leflunomide—systemic scleroderma	6.45e-05	0.000969	CcSEcCtD
Captopril—Abdominal pain—Leflunomide—systemic scleroderma	6.45e-05	0.000969	CcSEcCtD
Captopril—Feeling abnormal—Mycophenolic acid—systemic scleroderma	6.41e-05	0.000964	CcSEcCtD
Captopril—Chest pain—Mycophenolate mofetil—systemic scleroderma	6.4e-05	0.000963	CcSEcCtD
Captopril—Arthralgia—Mycophenolate mofetil—systemic scleroderma	6.4e-05	0.000963	CcSEcCtD
Captopril—Myalgia—Mycophenolate mofetil—systemic scleroderma	6.4e-05	0.000963	CcSEcCtD
Captopril—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	6.38e-05	0.00096	CcSEcCtD
Captopril—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	6.36e-05	0.000957	CcSEcCtD
Captopril—Insomnia—Lisinopril—systemic scleroderma	6.34e-05	0.000953	CcSEcCtD
Captopril—Discomfort—Mycophenolate mofetil—systemic scleroderma	6.33e-05	0.000952	CcSEcCtD
Captopril—Paraesthesia—Lisinopril—systemic scleroderma	6.29e-05	0.000946	CcSEcCtD
Captopril—Dry mouth—Mycophenolate mofetil—systemic scleroderma	6.26e-05	0.000942	CcSEcCtD
Captopril—Dyspnoea—Lisinopril—systemic scleroderma	6.25e-05	0.000939	CcSEcCtD
Captopril—Somnolence—Lisinopril—systemic scleroderma	6.23e-05	0.000937	CcSEcCtD
Captopril—Confusional state—Mycophenolate mofetil—systemic scleroderma	6.19e-05	0.000931	CcSEcCtD
Captopril—Dyspepsia—Lisinopril—systemic scleroderma	6.17e-05	0.000928	CcSEcCtD
Captopril—Body temperature increased—Mycophenolic acid—systemic scleroderma	6.15e-05	0.000925	CcSEcCtD
Captopril—Abdominal pain—Mycophenolic acid—systemic scleroderma	6.15e-05	0.000925	CcSEcCtD
Captopril—F2—G alpha (q) signalling events—EDN1—systemic scleroderma	6.14e-05	0.00136	CbGpPWpGaD
Captopril—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	6.14e-05	0.000923	CcSEcCtD
Captopril—Decreased appetite—Lisinopril—systemic scleroderma	6.09e-05	0.000916	CcSEcCtD
Captopril—F2—Peptide ligand-binding receptors—EDN1—systemic scleroderma	6.07e-05	0.00134	CbGpPWpGaD
Captopril—Eosinophilia—Methotrexate—systemic scleroderma	6.06e-05	0.000911	CcSEcCtD
Captopril—Fatigue—Lisinopril—systemic scleroderma	6.04e-05	0.000909	CcSEcCtD
Captopril—Shock—Mycophenolate mofetil—systemic scleroderma	6.04e-05	0.000908	CcSEcCtD
Captopril—ABCB1—digestive system—systemic scleroderma	6.04e-05	0.00104	CbGeAlD
Captopril—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	6.01e-05	0.000904	CcSEcCtD
Captopril—Pancreatitis—Methotrexate—systemic scleroderma	6e-05	0.000902	CcSEcCtD
Captopril—Constipation—Lisinopril—systemic scleroderma	5.99e-05	0.000901	CcSEcCtD
Captopril—Tachycardia—Mycophenolate mofetil—systemic scleroderma	5.99e-05	0.000901	CcSEcCtD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	5.97e-05	0.00132	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—IL1B—systemic scleroderma	5.96e-05	0.00132	CbGpPWpGaD
Captopril—REN—Metabolism of proteins—CCL2—systemic scleroderma	5.92e-05	0.00131	CbGpPWpGaD
Captopril—Diarrhoea—Azathioprine—systemic scleroderma	5.91e-05	0.000889	CcSEcCtD
Captopril—Anorexia—Mycophenolate mofetil—systemic scleroderma	5.85e-05	0.00088	CcSEcCtD
Captopril—Asthenia—Leflunomide—systemic scleroderma	5.85e-05	0.00088	CcSEcCtD
Captopril—Hallucination—Prednisone—systemic scleroderma	5.83e-05	0.000877	CcSEcCtD
Captopril—F2—Selenium Micronutrient Network—IL1B—systemic scleroderma	5.82e-05	0.00129	CbGpPWpGaD
Captopril—F2—Hemostasis—SELP—systemic scleroderma	5.81e-05	0.00129	CbGpPWpGaD
Captopril—Pancytopenia—Methotrexate—systemic scleroderma	5.81e-05	0.000873	CcSEcCtD
Captopril—Feeling abnormal—Lisinopril—systemic scleroderma	5.77e-05	0.000868	CcSEcCtD
Captopril—Pruritus—Leflunomide—systemic scleroderma	5.77e-05	0.000868	CcSEcCtD
Captopril—Hypotension—Mycophenolate mofetil—systemic scleroderma	5.74e-05	0.000863	CcSEcCtD
Captopril—Gastrointestinal pain—Lisinopril—systemic scleroderma	5.73e-05	0.000862	CcSEcCtD
Captopril—Neutropenia—Methotrexate—systemic scleroderma	5.72e-05	0.00086	CcSEcCtD
Captopril—Dizziness—Azathioprine—systemic scleroderma	5.71e-05	0.000859	CcSEcCtD
Captopril—MMP2—Metabolism of proteins—ACE—systemic scleroderma	5.63e-05	0.00125	CbGpPWpGaD
Captopril—REN—Metabolism of proteins—MMP2—systemic scleroderma	5.63e-05	0.00125	CbGpPWpGaD
Captopril—Erectile dysfunction—Methotrexate—systemic scleroderma	5.63e-05	0.000847	CcSEcCtD
Captopril—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	5.59e-05	0.000841	CcSEcCtD
Captopril—Photosensitivity reaction—Methotrexate—systemic scleroderma	5.58e-05	0.00084	CcSEcCtD
Captopril—Asthenia—Mycophenolic acid—systemic scleroderma	5.58e-05	0.000839	CcSEcCtD
Captopril—Diarrhoea—Leflunomide—systemic scleroderma	5.58e-05	0.000839	CcSEcCtD
Captopril—Insomnia—Mycophenolate mofetil—systemic scleroderma	5.55e-05	0.000835	CcSEcCtD
Captopril—Abdominal pain—Lisinopril—systemic scleroderma	5.54e-05	0.000833	CcSEcCtD
Captopril—Body temperature increased—Lisinopril—systemic scleroderma	5.54e-05	0.000833	CcSEcCtD
Captopril—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	5.51e-05	0.000829	CcSEcCtD
Captopril—Pruritus—Mycophenolic acid—systemic scleroderma	5.5e-05	0.000828	CcSEcCtD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	5.49e-05	0.00122	CbGpPWpGaD
Captopril—Vomiting—Azathioprine—systemic scleroderma	5.49e-05	0.000826	CcSEcCtD
Captopril—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	5.47e-05	0.000823	CcSEcCtD
Captopril—Somnolence—Mycophenolate mofetil—systemic scleroderma	5.46e-05	0.000821	CcSEcCtD
Captopril—Rash—Azathioprine—systemic scleroderma	5.44e-05	0.000819	CcSEcCtD
Captopril—Dermatitis—Azathioprine—systemic scleroderma	5.44e-05	0.000818	CcSEcCtD
Captopril—Flushing—Prednisone—systemic scleroderma	5.44e-05	0.000818	CcSEcCtD
Captopril—F2—Hemostasis—RHOB—systemic scleroderma	5.43e-05	0.0012	CbGpPWpGaD
Captopril—Headache—Azathioprine—systemic scleroderma	5.41e-05	0.000814	CcSEcCtD
Captopril—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	5.41e-05	0.0012	CbGpPWpGaD
Captopril—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	5.41e-05	0.000813	CcSEcCtD
Captopril—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	5.4e-05	0.000813	CcSEcCtD
Captopril—Dizziness—Leflunomide—systemic scleroderma	5.39e-05	0.000811	CcSEcCtD
Captopril—Renal failure—Methotrexate—systemic scleroderma	5.36e-05	0.000806	CcSEcCtD
Captopril—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	5.34e-05	0.000803	CcSEcCtD
Captopril—Diarrhoea—Mycophenolic acid—systemic scleroderma	5.32e-05	0.0008	CcSEcCtD
Captopril—Stomatitis—Methotrexate—systemic scleroderma	5.32e-05	0.000799	CcSEcCtD
Captopril—Constipation—Mycophenolate mofetil—systemic scleroderma	5.25e-05	0.00079	CcSEcCtD
Captopril—Vomiting—Leflunomide—systemic scleroderma	5.18e-05	0.00078	CcSEcCtD
Captopril—Alopecia—Prednisone—systemic scleroderma	5.18e-05	0.000778	CcSEcCtD
Captopril—Dizziness—Mycophenolic acid—systemic scleroderma	5.14e-05	0.000774	CcSEcCtD
Captopril—Rash—Leflunomide—systemic scleroderma	5.14e-05	0.000773	CcSEcCtD
Captopril—Dermatitis—Leflunomide—systemic scleroderma	5.14e-05	0.000773	CcSEcCtD
Captopril—Nausea—Azathioprine—systemic scleroderma	5.13e-05	0.000771	CcSEcCtD
Captopril—Headache—Leflunomide—systemic scleroderma	5.11e-05	0.000768	CcSEcCtD
Captopril—Agranulocytosis—Methotrexate—systemic scleroderma	5.09e-05	0.000765	CcSEcCtD
Captopril—MMP9—Extracellular matrix organization—MMP1—systemic scleroderma	5.08e-05	0.00112	CbGpPWpGaD
Captopril—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	5.06e-05	0.000761	CcSEcCtD
Captopril—ABCB1—lung—systemic scleroderma	5.04e-05	0.000865	CbGeAlD
Captopril—Asthenia—Lisinopril—systemic scleroderma	5.03e-05	0.000756	CcSEcCtD
Captopril—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	5.02e-05	0.000755	CcSEcCtD
Captopril—Pruritus—Lisinopril—systemic scleroderma	4.96e-05	0.000746	CcSEcCtD
Captopril—Vomiting—Mycophenolic acid—systemic scleroderma	4.95e-05	0.000744	CcSEcCtD
Captopril—F2—Hemostasis—CSK—systemic scleroderma	4.94e-05	0.0011	CbGpPWpGaD
Captopril—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	4.91e-05	0.00109	CbGpPWpGaD
Captopril—Rash—Mycophenolic acid—systemic scleroderma	4.9e-05	0.000738	CcSEcCtD
Captopril—Dermatitis—Mycophenolic acid—systemic scleroderma	4.9e-05	0.000737	CcSEcCtD
Captopril—Hepatitis—Methotrexate—systemic scleroderma	4.9e-05	0.000736	CcSEcCtD
Captopril—Headache—Mycophenolic acid—systemic scleroderma	4.87e-05	0.000733	CcSEcCtD
Captopril—Pharyngitis—Methotrexate—systemic scleroderma	4.86e-05	0.000731	CcSEcCtD
Captopril—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	4.85e-05	0.00073	CcSEcCtD
Captopril—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	4.85e-05	0.00073	CcSEcCtD
Captopril—Nausea—Leflunomide—systemic scleroderma	4.84e-05	0.000728	CcSEcCtD
Captopril—Vision blurred—Prednisone—systemic scleroderma	4.81e-05	0.000723	CcSEcCtD
Captopril—Diarrhoea—Lisinopril—systemic scleroderma	4.79e-05	0.000721	CcSEcCtD
Captopril—Ill-defined disorder—Prednisone—systemic scleroderma	4.73e-05	0.000712	CcSEcCtD
Captopril—Anaemia—Prednisone—systemic scleroderma	4.71e-05	0.000709	CcSEcCtD
Captopril—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	4.71e-05	0.00104	CbGpPWpGaD
Captopril—Angioedema—Prednisone—systemic scleroderma	4.66e-05	0.000701	CcSEcCtD
Captopril—F2—Hemostasis—ITGAM—systemic scleroderma	4.65e-05	0.00103	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—TGFB1—systemic scleroderma	4.63e-05	0.00103	CbGpPWpGaD
Captopril—Dizziness—Lisinopril—systemic scleroderma	4.63e-05	0.000697	CcSEcCtD
Captopril—Erythema multiforme—Methotrexate—systemic scleroderma	4.63e-05	0.000696	CcSEcCtD
Captopril—Nausea—Mycophenolic acid—systemic scleroderma	4.62e-05	0.000695	CcSEcCtD
Captopril—Malaise—Prednisone—systemic scleroderma	4.6e-05	0.000692	CcSEcCtD
Captopril—Syncope—Prednisone—systemic scleroderma	4.57e-05	0.000688	CcSEcCtD
Captopril—MMP2—Extracellular matrix organization—MMP9—systemic scleroderma	4.5e-05	0.000997	CbGpPWpGaD
Captopril—Loss of consciousness—Prednisone—systemic scleroderma	4.48e-05	0.000674	CcSEcCtD
Captopril—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	4.47e-05	0.000992	CbGpPWpGaD
Captopril—Vomiting—Lisinopril—systemic scleroderma	4.45e-05	0.00067	CcSEcCtD
Captopril—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	4.45e-05	0.000987	CbGpPWpGaD
Captopril—Rash—Lisinopril—systemic scleroderma	4.42e-05	0.000664	CcSEcCtD
Captopril—Dermatitis—Lisinopril—systemic scleroderma	4.41e-05	0.000664	CcSEcCtD
Captopril—Asthenia—Mycophenolate mofetil—systemic scleroderma	4.4e-05	0.000662	CcSEcCtD
Captopril—Headache—Lisinopril—systemic scleroderma	4.39e-05	0.00066	CcSEcCtD
Captopril—Pruritus—Mycophenolate mofetil—systemic scleroderma	4.34e-05	0.000653	CcSEcCtD
Captopril—Myalgia—Prednisone—systemic scleroderma	4.34e-05	0.000653	CcSEcCtD
Captopril—Arthralgia—Prednisone—systemic scleroderma	4.34e-05	0.000653	CcSEcCtD
Captopril—Alopecia—Methotrexate—systemic scleroderma	4.33e-05	0.000651	CcSEcCtD
Captopril—Discomfort—Prednisone—systemic scleroderma	4.29e-05	0.000645	CcSEcCtD
Captopril—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	4.23e-05	0.000938	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	4.21e-05	0.000932	CbGpPWpGaD
Captopril—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	4.2e-05	0.000632	CcSEcCtD
Captopril—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	4.18e-05	0.000926	CbGpPWpGaD
Captopril—Dysgeusia—Methotrexate—systemic scleroderma	4.17e-05	0.000628	CcSEcCtD
Captopril—Nausea—Lisinopril—systemic scleroderma	4.16e-05	0.000626	CcSEcCtD
Captopril—Anaphylactic shock—Prednisone—systemic scleroderma	4.16e-05	0.000626	CcSEcCtD
Captopril—F2—Peptide ligand-binding receptors—CCL2—systemic scleroderma	4.15e-05	0.000919	CbGpPWpGaD
Captopril—Shock—Prednisone—systemic scleroderma	4.09e-05	0.000616	CcSEcCtD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	4.07e-05	0.000902	CbGpPWpGaD
Captopril—Tachycardia—Prednisone—systemic scleroderma	4.06e-05	0.000611	CcSEcCtD
Captopril—Dizziness—Mycophenolate mofetil—systemic scleroderma	4.06e-05	0.000611	CcSEcCtD
Captopril—Vision blurred—Methotrexate—systemic scleroderma	4.02e-05	0.000604	CcSEcCtD
Captopril—Anorexia—Prednisone—systemic scleroderma	3.97e-05	0.000597	CcSEcCtD
Captopril—Ill-defined disorder—Methotrexate—systemic scleroderma	3.95e-05	0.000595	CcSEcCtD
Captopril—Anaemia—Methotrexate—systemic scleroderma	3.94e-05	0.000592	CcSEcCtD
Captopril—MMP9—Extracellular matrix organization—MMP2—systemic scleroderma	3.93e-05	0.000871	CbGpPWpGaD
Captopril—Vomiting—Mycophenolate mofetil—systemic scleroderma	3.9e-05	0.000587	CcSEcCtD
Captopril—Rash—Mycophenolate mofetil—systemic scleroderma	3.87e-05	0.000582	CcSEcCtD
Captopril—Dermatitis—Mycophenolate mofetil—systemic scleroderma	3.87e-05	0.000582	CcSEcCtD
Captopril—Headache—Mycophenolate mofetil—systemic scleroderma	3.85e-05	0.000578	CcSEcCtD
Captopril—Malaise—Methotrexate—systemic scleroderma	3.84e-05	0.000578	CcSEcCtD
Captopril—ALB—Folate Metabolism—CCL2—systemic scleroderma	3.83e-05	0.00085	CbGpPWpGaD
Captopril—MMP2—Axon guidance—MMP9—systemic scleroderma	3.82e-05	0.000847	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	3.8e-05	0.000843	CbGpPWpGaD
Captopril—Musculoskeletal discomfort—Prednisone—systemic scleroderma	3.79e-05	0.00057	CcSEcCtD
Captopril—Insomnia—Prednisone—systemic scleroderma	3.76e-05	0.000566	CcSEcCtD
Captopril—Paraesthesia—Prednisone—systemic scleroderma	3.74e-05	0.000562	CcSEcCtD
Captopril—Cough—Methotrexate—systemic scleroderma	3.72e-05	0.000559	CcSEcCtD
Captopril—MMP2—Extracellular matrix organization—TGFB1—systemic scleroderma	3.71e-05	0.000822	CbGpPWpGaD
Captopril—Dyspepsia—Prednisone—systemic scleroderma	3.66e-05	0.000551	CcSEcCtD
Captopril—Nausea—Mycophenolate mofetil—systemic scleroderma	3.65e-05	0.000548	CcSEcCtD
Captopril—Chest pain—Methotrexate—systemic scleroderma	3.63e-05	0.000546	CcSEcCtD
Captopril—Arthralgia—Methotrexate—systemic scleroderma	3.63e-05	0.000546	CcSEcCtD
Captopril—Myalgia—Methotrexate—systemic scleroderma	3.63e-05	0.000546	CcSEcCtD
Captopril—Decreased appetite—Prednisone—systemic scleroderma	3.62e-05	0.000544	CcSEcCtD
Captopril—MMP2—Metabolism of proteins—MMP1—systemic scleroderma	3.62e-05	0.000802	CbGpPWpGaD
Captopril—Fatigue—Prednisone—systemic scleroderma	3.59e-05	0.00054	CcSEcCtD
Captopril—Discomfort—Methotrexate—systemic scleroderma	3.58e-05	0.000539	CcSEcCtD
Captopril—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	3.57e-05	0.000792	CbGpPWpGaD
Captopril—Constipation—Prednisone—systemic scleroderma	3.56e-05	0.000535	CcSEcCtD
Captopril—Confusional state—Methotrexate—systemic scleroderma	3.51e-05	0.000527	CcSEcCtD
Captopril—Anaphylactic shock—Methotrexate—systemic scleroderma	3.48e-05	0.000523	CcSEcCtD
Captopril—F2—GPCR downstream signaling—RHOB—systemic scleroderma	3.43e-05	0.00076	CbGpPWpGaD
Captopril—Feeling abnormal—Prednisone—systemic scleroderma	3.43e-05	0.000516	CcSEcCtD
Captopril—Thrombocytopenia—Methotrexate—systemic scleroderma	3.41e-05	0.000512	CcSEcCtD
Captopril—Gastrointestinal pain—Prednisone—systemic scleroderma	3.4e-05	0.000512	CcSEcCtD
Captopril—MMP9—Axon guidance—MMP2—systemic scleroderma	3.33e-05	0.000739	CbGpPWpGaD
Captopril—Anorexia—Methotrexate—systemic scleroderma	3.32e-05	0.000499	CcSEcCtD
Captopril—Abdominal pain—Prednisone—systemic scleroderma	3.29e-05	0.000495	CcSEcCtD
Captopril—Body temperature increased—Prednisone—systemic scleroderma	3.29e-05	0.000495	CcSEcCtD
Captopril—LTA4H—Metabolism—NOS3—systemic scleroderma	3.28e-05	0.000728	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—MMP1—systemic scleroderma	3.25e-05	0.000721	CbGpPWpGaD
Captopril—Hypotension—Methotrexate—systemic scleroderma	3.25e-05	0.000489	CcSEcCtD
Captopril—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	3.17e-05	0.000477	CcSEcCtD
Captopril—Insomnia—Methotrexate—systemic scleroderma	3.15e-05	0.000473	CcSEcCtD
Captopril—Paraesthesia—Methotrexate—systemic scleroderma	3.12e-05	0.00047	CcSEcCtD
Captopril—F2—Signaling by GPCR—RHOB—systemic scleroderma	3.11e-05	0.00069	CbGpPWpGaD
Captopril—Dyspnoea—Methotrexate—systemic scleroderma	3.1e-05	0.000466	CcSEcCtD
Captopril—F2—GPCR ligand binding—EDN1—systemic scleroderma	3.1e-05	0.000687	CbGpPWpGaD
Captopril—Somnolence—Methotrexate—systemic scleroderma	3.09e-05	0.000465	CcSEcCtD
Captopril—MMP9—Signaling Pathways—SMAD7—systemic scleroderma	3.08e-05	0.000683	CbGpPWpGaD
Captopril—Dyspepsia—Methotrexate—systemic scleroderma	3.06e-05	0.00046	CcSEcCtD
Captopril—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	3.05e-05	0.000675	CbGpPWpGaD
Captopril—Decreased appetite—Methotrexate—systemic scleroderma	3.02e-05	0.000455	CcSEcCtD
Captopril—Fatigue—Methotrexate—systemic scleroderma	3e-05	0.000451	CcSEcCtD
Captopril—Asthenia—Prednisone—systemic scleroderma	2.99e-05	0.000449	CcSEcCtD
Captopril—Pruritus—Prednisone—systemic scleroderma	2.94e-05	0.000443	CcSEcCtD
Captopril—MMP2—Metabolism of proteins—CCL2—systemic scleroderma	2.94e-05	0.000652	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—IL1B—systemic scleroderma	2.91e-05	0.000644	CbGpPWpGaD
Captopril—Feeling abnormal—Methotrexate—systemic scleroderma	2.87e-05	0.000431	CcSEcCtD
Captopril—F2—Metabolism of proteins—ACE—systemic scleroderma	2.85e-05	0.000632	CbGpPWpGaD
Captopril—Diarrhoea—Prednisone—systemic scleroderma	2.85e-05	0.000428	CcSEcCtD
Captopril—Gastrointestinal pain—Methotrexate—systemic scleroderma	2.84e-05	0.000428	CcSEcCtD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	2.78e-05	0.000616	CbGpPWpGaD
Captopril—Dizziness—Prednisone—systemic scleroderma	2.75e-05	0.000414	CcSEcCtD
Captopril—Body temperature increased—Methotrexate—systemic scleroderma	2.75e-05	0.000413	CcSEcCtD
Captopril—Abdominal pain—Methotrexate—systemic scleroderma	2.75e-05	0.000413	CcSEcCtD
Captopril—MMP2—Developmental Biology—MMP9—systemic scleroderma	2.73e-05	0.000604	CbGpPWpGaD
Captopril—Vomiting—Prednisone—systemic scleroderma	2.65e-05	0.000398	CcSEcCtD
Captopril—ACE—Metabolism of proteins—CCL2—systemic scleroderma	2.65e-05	0.000586	CbGpPWpGaD
Captopril—Rash—Prednisone—systemic scleroderma	2.62e-05	0.000395	CcSEcCtD
Captopril—Dermatitis—Prednisone—systemic scleroderma	2.62e-05	0.000394	CcSEcCtD
Captopril—Headache—Prednisone—systemic scleroderma	2.61e-05	0.000392	CcSEcCtD
Captopril—ACE—Metabolism of proteins—MMP2—systemic scleroderma	2.52e-05	0.000558	CbGpPWpGaD
Captopril—Asthenia—Methotrexate—systemic scleroderma	2.5e-05	0.000375	CcSEcCtD
Captopril—Nausea—Prednisone—systemic scleroderma	2.47e-05	0.000372	CcSEcCtD
Captopril—Pruritus—Methotrexate—systemic scleroderma	2.46e-05	0.00037	CcSEcCtD
Captopril—MMP9—Extracellular matrix organization—TGFB1—systemic scleroderma	2.43e-05	0.000539	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—RHOB—systemic scleroderma	2.38e-05	0.000528	CbGpPWpGaD
Captopril—Diarrhoea—Methotrexate—systemic scleroderma	2.38e-05	0.000358	CcSEcCtD
Captopril—MMP9—Developmental Biology—MMP2—systemic scleroderma	2.38e-05	0.000527	CbGpPWpGaD
Captopril—F2—Signaling Pathways—SMAD7—systemic scleroderma	2.38e-05	0.000527	CbGpPWpGaD
Captopril—F2—Hemostasis—MMP1—systemic scleroderma	2.33e-05	0.000516	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	2.31e-05	0.000512	CbGpPWpGaD
Captopril—ALB—Hemostasis—SELP—systemic scleroderma	2.31e-05	0.000511	CbGpPWpGaD
Captopril—Dizziness—Methotrexate—systemic scleroderma	2.3e-05	0.000346	CcSEcCtD
Captopril—MMP9—Signaling Pathways—HSPG2—systemic scleroderma	2.25e-05	0.000498	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—TGFB1—systemic scleroderma	2.25e-05	0.000498	CbGpPWpGaD
Captopril—Vomiting—Methotrexate—systemic scleroderma	2.21e-05	0.000333	CcSEcCtD
Captopril—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	2.21e-05	0.000489	CbGpPWpGaD
Captopril—Rash—Methotrexate—systemic scleroderma	2.19e-05	0.00033	CcSEcCtD
Captopril—Dermatitis—Methotrexate—systemic scleroderma	2.19e-05	0.000329	CcSEcCtD
Captopril—Headache—Methotrexate—systemic scleroderma	2.18e-05	0.000328	CcSEcCtD
Captopril—MMP9—Signaling Pathways—CSK—systemic scleroderma	2.17e-05	0.000481	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	2.17e-05	0.00048	CbGpPWpGaD
Captopril—ALB—Hemostasis—RHOB—systemic scleroderma	2.15e-05	0.000477	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—CCL2—systemic scleroderma	2.12e-05	0.000469	CbGpPWpGaD
Captopril—Nausea—Methotrexate—systemic scleroderma	2.07e-05	0.000311	CcSEcCtD
Captopril—ALB—Hemostasis—CSK—systemic scleroderma	1.96e-05	0.000435	CbGpPWpGaD
Captopril—ALB—Platelet degranulation—TGFB1—systemic scleroderma	1.94e-05	0.000429	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.85e-05	0.00041	CbGpPWpGaD
Captopril—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	1.85e-05	0.000409	CbGpPWpGaD
Captopril—ALB—Hemostasis—ITGAM—systemic scleroderma	1.84e-05	0.000409	CbGpPWpGaD
Captopril—F2—Signaling Pathways—RHOB—systemic scleroderma	1.84e-05	0.000408	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—MMP1—systemic scleroderma	1.83e-05	0.000406	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—EDN1—systemic scleroderma	1.75e-05	0.000388	CbGpPWpGaD
Captopril—F2—Signaling Pathways—HSPG2—systemic scleroderma	1.73e-05	0.000385	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	1.71e-05	0.00038	CbGpPWpGaD
Captopril—F2—Hemostasis—NOS3—systemic scleroderma	1.69e-05	0.000374	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CSK—systemic scleroderma	1.68e-05	0.000371	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—EDN1—systemic scleroderma	1.59e-05	0.000352	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—CCL2—systemic scleroderma	1.49e-05	0.00033	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—TGFB1—systemic scleroderma	1.47e-05	0.000327	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—MMP2—systemic scleroderma	1.42e-05	0.000314	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.4e-05	0.000311	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—EDN1—systemic scleroderma	1.22e-05	0.00027	CbGpPWpGaD
Captopril—F2—Hemostasis—TGFB1—systemic scleroderma	1.12e-05	0.000247	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—CCL2—systemic scleroderma	1.09e-05	0.000241	CbGpPWpGaD
Captopril—F2—Signaling Pathways—EDN1—systemic scleroderma	9.39e-06	0.000208	CbGpPWpGaD
Captopril—ALB—Hemostasis—MMP1—systemic scleroderma	9.24e-06	0.000205	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	8.59e-06	0.00019	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	8.46e-06	0.000188	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CCL2—systemic scleroderma	8.32e-06	0.000184	CbGpPWpGaD
Captopril—ALB—Metabolism—HSPG2—systemic scleroderma	8.23e-06	0.000182	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—NOS3—systemic scleroderma	7.41e-06	0.000164	CbGpPWpGaD
Captopril—ABCB1—Metabolism—HSPG2—systemic scleroderma	7.21e-06	0.00016	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—HSPG2—systemic scleroderma	6.8e-06	0.000151	CbGpPWpGaD
Captopril—ALB—Hemostasis—NOS3—systemic scleroderma	6.7e-06	0.000148	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CCL2—systemic scleroderma	6.42e-06	0.000142	CbGpPWpGaD
Captopril—ALB—Metabolism—CTGF—systemic scleroderma	6.24e-06	0.000138	CbGpPWpGaD
Captopril—F2—Signaling Pathways—NOS3—systemic scleroderma	5.72e-06	0.000127	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CTGF—systemic scleroderma	5.47e-06	0.000121	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CTGF—systemic scleroderma	5.15e-06	0.000114	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TGFB1—systemic scleroderma	4.9e-06	0.000109	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MMP9—systemic scleroderma	4.59e-06	0.000102	CbGpPWpGaD
Captopril—ALB—Hemostasis—TGFB1—systemic scleroderma	4.43e-06	9.82e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TGFB1—systemic scleroderma	3.78e-06	8.39e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—NOS3—systemic scleroderma	2.72e-06	6.02e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—NOS3—systemic scleroderma	2.38e-06	5.27e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—NOS3—systemic scleroderma	2.24e-06	4.97e-05	CbGpPWpGaD
